Review



anti cstf77  (Bethyl)


Bioz Verified Symbol Bethyl is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Bethyl anti cstf77
    Anti Cstf77, supplied by Bethyl, used in various techniques. Bioz Stars score: 93/100, based on 17 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+cstf77/CSTF77+Antibody/pm39798570-418-40-41
    Average 93 stars, based on 17 article reviews
    anti cstf77 - by Bioz Stars, 2026-09
    93/100 stars

    Images

    Related Articles

    other:


    Article Title: Human TREX component Thoc5 affects alternative polyadenylation site choice by recruiting mammalian cleavage factor I
    Article Snippet: Anti-SR (16H3, Zymed) , anti-CPSF68 (CFIm68), anti-CPSF73, anti-CstF64, anti-CstF77, anti-hFip1 (Bethyl Laboratories), anti-mouse IgG (Zymed or Rockland), anti-CPSF100 (Sigma), anti-β-actin (AC-15, Sigma), anti-Thoc6 (Abnova), anti-Aly (11G5, Abcam) and normal mouse IgG (Santa Cruz) antibodies were commercially acquired.



    Similar Products

    93
    Bethyl anti cstf77
    Anti Cstf77, supplied by Bethyl, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+cstf77/CSTF77+Antibody/pm39798570-418-40-41
    Average 93 stars, based on 1 article reviews
    anti cstf77 - by Bioz Stars, 2026-09
    93/100 stars
      Buy from Supplier

    93
    Bethyl cstf3
    A Construction of platinum-resistant OC cell lines A2780-DDP and OVCAR3-DDP cells. Western blot ( B ) and RT‒qPCR ( C ) were performed to detect the expression of <t>CSTF3</t> in A2780-DDP, OVCAR3-DDP and corresponding parental cells. D CSTF3 protein was measured to confirm the knockdown efficiency in A2780-DDP and OVCAR3-DDP cells. E Cell viability was evaluated to measure the IC50 of platinum after knockdown of CSTF3 and treatment with gradient concentrations of platinum in A2780-DDP and OVCAR3-DDP cells. F A2780-DDP and OVCAR3-DDP cells were treated with 100 μM and 40 μM platinum for 6 h respectively. Colony formation assay was performed with control and CSTF3 knockdown A2780-DDP and OVCAR3-DDP cells treated with or without platinum. G Western blot was performed to verify CSTF3 knockdown efficiency in WT A2780 and OVCAR3 cells. H A2780 and OVCAR3 cells with CSTF3 knockdown were treated with different concentrations of platinum, and cell survival was determined. I A2780 and OVCAR3 cells were treated with 20 μM and 5 μM platinum for 6 h respectively. Colony formation assays were performed in A2780 and OVCAR3 cells treated with or without platinum after CSTF3 knockdown. J FLAG-NC and FLAG-CSTF3 were stably transfected into A2780 and OVCAR3 cells. Then, cell viability curves ( K ) and colony formation assays ( L ) were performed to measure the sensitivity of cells to platinum after overexpression of CSTF3. *P < 0.05, **P < 0.01, ***P < 0.001 vs. shNC.
    Cstf3, supplied by Bethyl, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+cstf77/CSTF77+Antibody/pmc11187223-274-6-7
    Average 93 stars, based on 1 article reviews
    cstf3 - by Bioz Stars, 2026-09
    93/100 stars
      Buy from Supplier

    93
    Bethyl cstf77
    A Construction of platinum-resistant OC cell lines A2780-DDP and OVCAR3-DDP cells. Western blot ( B ) and RT‒qPCR ( C ) were performed to detect the expression of <t>CSTF3</t> in A2780-DDP, OVCAR3-DDP and corresponding parental cells. D CSTF3 protein was measured to confirm the knockdown efficiency in A2780-DDP and OVCAR3-DDP cells. E Cell viability was evaluated to measure the IC50 of platinum after knockdown of CSTF3 and treatment with gradient concentrations of platinum in A2780-DDP and OVCAR3-DDP cells. F A2780-DDP and OVCAR3-DDP cells were treated with 100 μM and 40 μM platinum for 6 h respectively. Colony formation assay was performed with control and CSTF3 knockdown A2780-DDP and OVCAR3-DDP cells treated with or without platinum. G Western blot was performed to verify CSTF3 knockdown efficiency in WT A2780 and OVCAR3 cells. H A2780 and OVCAR3 cells with CSTF3 knockdown were treated with different concentrations of platinum, and cell survival was determined. I A2780 and OVCAR3 cells were treated with 20 μM and 5 μM platinum for 6 h respectively. Colony formation assays were performed in A2780 and OVCAR3 cells treated with or without platinum after CSTF3 knockdown. J FLAG-NC and FLAG-CSTF3 were stably transfected into A2780 and OVCAR3 cells. Then, cell viability curves ( K ) and colony formation assays ( L ) were performed to measure the sensitivity of cells to platinum after overexpression of CSTF3. *P < 0.05, **P < 0.01, ***P < 0.001 vs. shNC.
    Cstf77, supplied by Bethyl, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+cstf77/CSTF77+Antibody/bio_rxiv__2023__02__24__529985-80-22-23
    Average 93 stars, based on 1 article reviews
    cstf77 - by Bioz Stars, 2026-09
    93/100 stars
      Buy from Supplier

    93
    Bethyl a301 096a
    A Construction of platinum-resistant OC cell lines A2780-DDP and OVCAR3-DDP cells. Western blot ( B ) and RT‒qPCR ( C ) were performed to detect the expression of <t>CSTF3</t> in A2780-DDP, OVCAR3-DDP and corresponding parental cells. D CSTF3 protein was measured to confirm the knockdown efficiency in A2780-DDP and OVCAR3-DDP cells. E Cell viability was evaluated to measure the IC50 of platinum after knockdown of CSTF3 and treatment with gradient concentrations of platinum in A2780-DDP and OVCAR3-DDP cells. F A2780-DDP and OVCAR3-DDP cells were treated with 100 μM and 40 μM platinum for 6 h respectively. Colony formation assay was performed with control and CSTF3 knockdown A2780-DDP and OVCAR3-DDP cells treated with or without platinum. G Western blot was performed to verify CSTF3 knockdown efficiency in WT A2780 and OVCAR3 cells. H A2780 and OVCAR3 cells with CSTF3 knockdown were treated with different concentrations of platinum, and cell survival was determined. I A2780 and OVCAR3 cells were treated with 20 μM and 5 μM platinum for 6 h respectively. Colony formation assays were performed in A2780 and OVCAR3 cells treated with or without platinum after CSTF3 knockdown. J FLAG-NC and FLAG-CSTF3 were stably transfected into A2780 and OVCAR3 cells. Then, cell viability curves ( K ) and colony formation assays ( L ) were performed to measure the sensitivity of cells to platinum after overexpression of CSTF3. *P < 0.05, **P < 0.01, ***P < 0.001 vs. shNC.
    A301 096a, supplied by Bethyl, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+cstf77/CSTF77+Antibody/pm35914531-259-138-136
    Average 93 stars, based on 1 article reviews
    a301 096a - by Bioz Stars, 2026-09
    93/100 stars
      Buy from Supplier

    93
    Santa Cruz Biotechnology mouse monoclonal anti cstf77 antibody

    Mouse Monoclonal Anti Cstf77 Antibody, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/anti+cstf77/CstF-77+Antibody/pmc09385686-13-0-6
    Average 93 stars, based on 1 article reviews
    mouse monoclonal anti cstf77 antibody - by Bioz Stars, 2026-09
    93/100 stars
      Buy from Supplier

    Image Search Results


    A Construction of platinum-resistant OC cell lines A2780-DDP and OVCAR3-DDP cells. Western blot ( B ) and RT‒qPCR ( C ) were performed to detect the expression of CSTF3 in A2780-DDP, OVCAR3-DDP and corresponding parental cells. D CSTF3 protein was measured to confirm the knockdown efficiency in A2780-DDP and OVCAR3-DDP cells. E Cell viability was evaluated to measure the IC50 of platinum after knockdown of CSTF3 and treatment with gradient concentrations of platinum in A2780-DDP and OVCAR3-DDP cells. F A2780-DDP and OVCAR3-DDP cells were treated with 100 μM and 40 μM platinum for 6 h respectively. Colony formation assay was performed with control and CSTF3 knockdown A2780-DDP and OVCAR3-DDP cells treated with or without platinum. G Western blot was performed to verify CSTF3 knockdown efficiency in WT A2780 and OVCAR3 cells. H A2780 and OVCAR3 cells with CSTF3 knockdown were treated with different concentrations of platinum, and cell survival was determined. I A2780 and OVCAR3 cells were treated with 20 μM and 5 μM platinum for 6 h respectively. Colony formation assays were performed in A2780 and OVCAR3 cells treated with or without platinum after CSTF3 knockdown. J FLAG-NC and FLAG-CSTF3 were stably transfected into A2780 and OVCAR3 cells. Then, cell viability curves ( K ) and colony formation assays ( L ) were performed to measure the sensitivity of cells to platinum after overexpression of CSTF3. *P < 0.05, **P < 0.01, ***P < 0.001 vs. shNC.

    Journal: Cell Death & Disease

    Article Title: CSTF3 contributes to platinum resistance in ovarian cancer through alternative polyadenylation of lncRNA NEAT1 and generating the short isoform NEAT1_1

    doi: 10.1038/s41419-024-06816-1

    Figure Lengend Snippet: A Construction of platinum-resistant OC cell lines A2780-DDP and OVCAR3-DDP cells. Western blot ( B ) and RT‒qPCR ( C ) were performed to detect the expression of CSTF3 in A2780-DDP, OVCAR3-DDP and corresponding parental cells. D CSTF3 protein was measured to confirm the knockdown efficiency in A2780-DDP and OVCAR3-DDP cells. E Cell viability was evaluated to measure the IC50 of platinum after knockdown of CSTF3 and treatment with gradient concentrations of platinum in A2780-DDP and OVCAR3-DDP cells. F A2780-DDP and OVCAR3-DDP cells were treated with 100 μM and 40 μM platinum for 6 h respectively. Colony formation assay was performed with control and CSTF3 knockdown A2780-DDP and OVCAR3-DDP cells treated with or without platinum. G Western blot was performed to verify CSTF3 knockdown efficiency in WT A2780 and OVCAR3 cells. H A2780 and OVCAR3 cells with CSTF3 knockdown were treated with different concentrations of platinum, and cell survival was determined. I A2780 and OVCAR3 cells were treated with 20 μM and 5 μM platinum for 6 h respectively. Colony formation assays were performed in A2780 and OVCAR3 cells treated with or without platinum after CSTF3 knockdown. J FLAG-NC and FLAG-CSTF3 were stably transfected into A2780 and OVCAR3 cells. Then, cell viability curves ( K ) and colony formation assays ( L ) were performed to measure the sensitivity of cells to platinum after overexpression of CSTF3. *P < 0.05, **P < 0.01, ***P < 0.001 vs. shNC.

    Article Snippet: The primary antibodies were as follows: CSTF3 (Bethyl, A301-096A), PI3K (Abcam, ab151549), AKT (Proteintech, 60203-2-Ig), mTOR (CST, 2983 T), phospho-PI3K (CST, 4228 S), phospho-AKT (CST, 4060 S), phospho-mTOR (CST, 5536 S), FLAG-tag (MBL, M185-3L, PM020), and GAPDH (Proteintech, 60004-1-Ig).

    Techniques: Western Blot, Expressing, Knockdown, Colony Assay, Control, Stable Transfection, Transfection, Over Expression

    OVCAR3 cells transfected with CSTF3 knockdown or negative control constructs were injected subcutaneously into BALB/c nude mice. The xenografted mice were treated with or without DDP (4 mg/kg) through intraperitoneal injection once every 6 days. A Photo of representative tumors from six groups of xenografted nude mice on the 22nd day. B The growth of tumor volumes was monitored every 3 days beginning on the 7th day. C Tumor weights are presented as the mean ± SD from five mice per group. D , E HE staining was performed to evaluate tissue morphology, and IHC was performed to visualize Ki-67- and Caspase-3-positive staining in xenografted tumors. *P < 0.05, **P < 0.01, ***P < 0.001 vs. shNC.

    Journal: Cell Death & Disease

    Article Title: CSTF3 contributes to platinum resistance in ovarian cancer through alternative polyadenylation of lncRNA NEAT1 and generating the short isoform NEAT1_1

    doi: 10.1038/s41419-024-06816-1

    Figure Lengend Snippet: OVCAR3 cells transfected with CSTF3 knockdown or negative control constructs were injected subcutaneously into BALB/c nude mice. The xenografted mice were treated with or without DDP (4 mg/kg) through intraperitoneal injection once every 6 days. A Photo of representative tumors from six groups of xenografted nude mice on the 22nd day. B The growth of tumor volumes was monitored every 3 days beginning on the 7th day. C Tumor weights are presented as the mean ± SD from five mice per group. D , E HE staining was performed to evaluate tissue morphology, and IHC was performed to visualize Ki-67- and Caspase-3-positive staining in xenografted tumors. *P < 0.05, **P < 0.01, ***P < 0.001 vs. shNC.

    Article Snippet: The primary antibodies were as follows: CSTF3 (Bethyl, A301-096A), PI3K (Abcam, ab151549), AKT (Proteintech, 60203-2-Ig), mTOR (CST, 2983 T), phospho-PI3K (CST, 4228 S), phospho-AKT (CST, 4060 S), phospho-mTOR (CST, 5536 S), FLAG-tag (MBL, M185-3L, PM020), and GAPDH (Proteintech, 60004-1-Ig).

    Techniques: Transfection, Knockdown, Negative Control, Construct, Injection, Staining

    A CSTF3 knockdown induced an APA shift of target genes in A2780 cells, left: scatterplot of the 3’UTR alteration in CSTF3 knockdown cells when compared with the control cells, right: the usage of proximal and distal PAS in CSTF3 knockdown cells. B Detection of APA events in CSTF3 knockdown OVCAR3 cells, combining 3’UTR alteration and usage of PAS. C Filtering out the directly bound target genes of CSTF3 by eCLIP-seq. D The consensus sequences of CSTF3 binding sites detected by HOMER motif analysis with eCLIP-seq data. E Distribution of CSTF3-targeted transcript types (left) and CSTF3 binding sites within different regions (right) as identified through eCLIP-seq. F The Venn diagram screened the candidate target genes using CSTF3 eCLIP-seq, A2780 and OVCAR3 PAS-seq data. G IGV genome browser showing the PAS usage of the NEAT1 3′UTR by eCLIP-seq. H Schematic diagram for primer design of short and long NEAT1 transcripts to validate the NEAT1 APA regulation by CSTF3. I Histogram showing the relative expression of the NEAT1 isoform with the distal PAS (dPAS) relative to that with the proximal PAS (pPAS) when CSTF3 was downregulated in A2780, A2780-DDP, OVCAR3 and OVCAR3-DDP cells compared with the negative control. J CLIP-qPCR detected the interaction between CSTF3 and NEAT1. K RT-qPCR was used to detect the relative expression of NEAT1 in A2780-DDP, OVCAR3-DDP and corresponding parental cells. *P < 0.05, **P < 0.01, ***P < 0.001.

    Journal: Cell Death & Disease

    Article Title: CSTF3 contributes to platinum resistance in ovarian cancer through alternative polyadenylation of lncRNA NEAT1 and generating the short isoform NEAT1_1

    doi: 10.1038/s41419-024-06816-1

    Figure Lengend Snippet: A CSTF3 knockdown induced an APA shift of target genes in A2780 cells, left: scatterplot of the 3’UTR alteration in CSTF3 knockdown cells when compared with the control cells, right: the usage of proximal and distal PAS in CSTF3 knockdown cells. B Detection of APA events in CSTF3 knockdown OVCAR3 cells, combining 3’UTR alteration and usage of PAS. C Filtering out the directly bound target genes of CSTF3 by eCLIP-seq. D The consensus sequences of CSTF3 binding sites detected by HOMER motif analysis with eCLIP-seq data. E Distribution of CSTF3-targeted transcript types (left) and CSTF3 binding sites within different regions (right) as identified through eCLIP-seq. F The Venn diagram screened the candidate target genes using CSTF3 eCLIP-seq, A2780 and OVCAR3 PAS-seq data. G IGV genome browser showing the PAS usage of the NEAT1 3′UTR by eCLIP-seq. H Schematic diagram for primer design of short and long NEAT1 transcripts to validate the NEAT1 APA regulation by CSTF3. I Histogram showing the relative expression of the NEAT1 isoform with the distal PAS (dPAS) relative to that with the proximal PAS (pPAS) when CSTF3 was downregulated in A2780, A2780-DDP, OVCAR3 and OVCAR3-DDP cells compared with the negative control. J CLIP-qPCR detected the interaction between CSTF3 and NEAT1. K RT-qPCR was used to detect the relative expression of NEAT1 in A2780-DDP, OVCAR3-DDP and corresponding parental cells. *P < 0.05, **P < 0.01, ***P < 0.001.

    Article Snippet: The primary antibodies were as follows: CSTF3 (Bethyl, A301-096A), PI3K (Abcam, ab151549), AKT (Proteintech, 60203-2-Ig), mTOR (CST, 2983 T), phospho-PI3K (CST, 4228 S), phospho-AKT (CST, 4060 S), phospho-mTOR (CST, 5536 S), FLAG-tag (MBL, M185-3L, PM020), and GAPDH (Proteintech, 60004-1-Ig).

    Techniques: Knockdown, Control, Binding Assay, Expressing, Negative Control, Quantitative RT-PCR

    A The IC50 values were evaluated when silencing the expression of NEAT1 and NEAT1_2 in A2780, OVCAR3 and corresponding platinum-resistant cells compared with the negative control. B A2780, OVCAR3, A2780-DDP and OVCAR3-DDP cells were treated with 20 μM, 5 μM, 100 μM and 40 μM platinum for 6 h respectively. Colony formation assay was performed to measure the sensitivity of the drug when silencing the expression of NEAT1 and NEAT1_2 in A2780, OVCAR3 and corresponding platinum-resistant cells treated with or without platinum. C , D The IC50 values and colony formation were evaluated when NEAT1_1 was overexpressed in A2780, OVCAR3 and platinum-resistant cells with CSTF3 knockdown treated with platinum or not. *P < 0.05, **P < 0.01, ***P < 0.001. ns not significant.

    Journal: Cell Death & Disease

    Article Title: CSTF3 contributes to platinum resistance in ovarian cancer through alternative polyadenylation of lncRNA NEAT1 and generating the short isoform NEAT1_1

    doi: 10.1038/s41419-024-06816-1

    Figure Lengend Snippet: A The IC50 values were evaluated when silencing the expression of NEAT1 and NEAT1_2 in A2780, OVCAR3 and corresponding platinum-resistant cells compared with the negative control. B A2780, OVCAR3, A2780-DDP and OVCAR3-DDP cells were treated with 20 μM, 5 μM, 100 μM and 40 μM platinum for 6 h respectively. Colony formation assay was performed to measure the sensitivity of the drug when silencing the expression of NEAT1 and NEAT1_2 in A2780, OVCAR3 and corresponding platinum-resistant cells treated with or without platinum. C , D The IC50 values and colony formation were evaluated when NEAT1_1 was overexpressed in A2780, OVCAR3 and platinum-resistant cells with CSTF3 knockdown treated with platinum or not. *P < 0.05, **P < 0.01, ***P < 0.001. ns not significant.

    Article Snippet: The primary antibodies were as follows: CSTF3 (Bethyl, A301-096A), PI3K (Abcam, ab151549), AKT (Proteintech, 60203-2-Ig), mTOR (CST, 2983 T), phospho-PI3K (CST, 4228 S), phospho-AKT (CST, 4060 S), phospho-mTOR (CST, 5536 S), FLAG-tag (MBL, M185-3L, PM020), and GAPDH (Proteintech, 60004-1-Ig).

    Techniques: Expressing, Negative Control, Colony Assay, Knockdown

    Immunofluorescence assays were performed with CSTF3 knockdown in A2780 ( A ) and OVCAR3 ( B ) cells, and images of DAPI (blue), CSTF3 (green), PSPC1 (red, left) and SFPQ (red, right) were obtained. C Immunofluorescence of A2780 and OVCAR3 cells transfected with si-NEAT1, si-NEAT1_2 and the negative control. DAPI (blue), PSPC1 (green) and SFPQ (red) were detected.

    Journal: Cell Death & Disease

    Article Title: CSTF3 contributes to platinum resistance in ovarian cancer through alternative polyadenylation of lncRNA NEAT1 and generating the short isoform NEAT1_1

    doi: 10.1038/s41419-024-06816-1

    Figure Lengend Snippet: Immunofluorescence assays were performed with CSTF3 knockdown in A2780 ( A ) and OVCAR3 ( B ) cells, and images of DAPI (blue), CSTF3 (green), PSPC1 (red, left) and SFPQ (red, right) were obtained. C Immunofluorescence of A2780 and OVCAR3 cells transfected with si-NEAT1, si-NEAT1_2 and the negative control. DAPI (blue), PSPC1 (green) and SFPQ (red) were detected.

    Article Snippet: The primary antibodies were as follows: CSTF3 (Bethyl, A301-096A), PI3K (Abcam, ab151549), AKT (Proteintech, 60203-2-Ig), mTOR (CST, 2983 T), phospho-PI3K (CST, 4228 S), phospho-AKT (CST, 4060 S), phospho-mTOR (CST, 5536 S), FLAG-tag (MBL, M185-3L, PM020), and GAPDH (Proteintech, 60004-1-Ig).

    Techniques: Immunofluorescence, Knockdown, Transfection, Negative Control

    A Overlap of upregulated and downregulated genes in A2780 and OVCAR3 cells when CSTF3 was knocked down. B KEGG enrichment analysis for overlap of upregulated and downregulated genes. C Overlap of differentially expressed genes (DEGs) in OVCAR3 cells when NEAT1 and NEAT1_2 were silenced. D KEGG analysis of DEGs for silencing NEAT1. E KEGG analysis of DEGs for silencing NEAT1_2. F Histogram of KEGG analysis for the independent DEGs list with NEAT1 and NEAT1_2 silenced. G KEGG enrichment analysis of the individual DEGs list with NEAT1 silenced. H KEGG enrichment analysis of the individual DEGs list with NEAT1_2 silenced. I The levels of PI3K/AKT/mTOR pathway-related proteins were detected by western blot when CSTF3 was downregulated in A2780 and OVCAR3 cells. J Western blot was used to measure the levels of PI3K/AKT/mTOR pathway-related proteins with NEAT1 or NEAT1_2 siRNA transfected into A2780 and OVCAR3 cells.

    Journal: Cell Death & Disease

    Article Title: CSTF3 contributes to platinum resistance in ovarian cancer through alternative polyadenylation of lncRNA NEAT1 and generating the short isoform NEAT1_1

    doi: 10.1038/s41419-024-06816-1

    Figure Lengend Snippet: A Overlap of upregulated and downregulated genes in A2780 and OVCAR3 cells when CSTF3 was knocked down. B KEGG enrichment analysis for overlap of upregulated and downregulated genes. C Overlap of differentially expressed genes (DEGs) in OVCAR3 cells when NEAT1 and NEAT1_2 were silenced. D KEGG analysis of DEGs for silencing NEAT1. E KEGG analysis of DEGs for silencing NEAT1_2. F Histogram of KEGG analysis for the independent DEGs list with NEAT1 and NEAT1_2 silenced. G KEGG enrichment analysis of the individual DEGs list with NEAT1 silenced. H KEGG enrichment analysis of the individual DEGs list with NEAT1_2 silenced. I The levels of PI3K/AKT/mTOR pathway-related proteins were detected by western blot when CSTF3 was downregulated in A2780 and OVCAR3 cells. J Western blot was used to measure the levels of PI3K/AKT/mTOR pathway-related proteins with NEAT1 or NEAT1_2 siRNA transfected into A2780 and OVCAR3 cells.

    Article Snippet: The primary antibodies were as follows: CSTF3 (Bethyl, A301-096A), PI3K (Abcam, ab151549), AKT (Proteintech, 60203-2-Ig), mTOR (CST, 2983 T), phospho-PI3K (CST, 4228 S), phospho-AKT (CST, 4060 S), phospho-mTOR (CST, 5536 S), FLAG-tag (MBL, M185-3L, PM020), and GAPDH (Proteintech, 60004-1-Ig).

    Techniques: Western Blot, Transfection

    Diagram of the regulatory mechanism and function underlying CSTF3 mediating the platinum resistance of OC cells .

    Journal: Cell Death & Disease

    Article Title: CSTF3 contributes to platinum resistance in ovarian cancer through alternative polyadenylation of lncRNA NEAT1 and generating the short isoform NEAT1_1

    doi: 10.1038/s41419-024-06816-1

    Figure Lengend Snippet: Diagram of the regulatory mechanism and function underlying CSTF3 mediating the platinum resistance of OC cells .

    Article Snippet: The primary antibodies were as follows: CSTF3 (Bethyl, A301-096A), PI3K (Abcam, ab151549), AKT (Proteintech, 60203-2-Ig), mTOR (CST, 2983 T), phospho-PI3K (CST, 4228 S), phospho-AKT (CST, 4060 S), phospho-mTOR (CST, 5536 S), FLAG-tag (MBL, M185-3L, PM020), and GAPDH (Proteintech, 60004-1-Ig).

    Techniques:

    Journal: iScience

    Article Title: Targeting the mRNA endonuclease CPSF73 inhibits breast cancer cell migration, invasion, and self-renewal

    doi: 10.1016/j.isci.2022.104804

    Figure Lengend Snippet:

    Article Snippet: Mouse monoclonal anti-CstF77 antibody (G-5) , Santa Cruz Biotechnology , Cat#sc-376575; RRID: AB_11151026.

    Techniques: Recombinant, Cell Viability Assay, shRNA, Control, Plasmid Preparation, Software